This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amsler, K. M.
Right arrow Articles by Bush, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amsler, K. M.
Right arrow Articles by Bush, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2008, p. 3418-3423, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.00336-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Ceftobiprole against Pathogens from Two Phase 3 Clinical Trials of Complicated Skin and Skin Structure Infections{triangledown}

Karen M. Amsler,1* Todd A. Davies,1 Wenchi Shang,1 Michael R. Jacobs,2 and Karen Bush1

Johnson & Johnson Pharmaceutical Research & Development L.L.C., Raritan, New Jersey,1 Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio2

Received 11 March 2008/ Returned for modification 10 April 2008/ Accepted 21 June 2008

In phase 3 clinical trials for ceftobiprole treatment of complicated skin and skin structure infections, 1,219 gram-positive and 276 gram-negative aerobic baseline pathogens were identified. Ceftobiprole inhibited all staphylococcal isolates, including methicillin-resistant strains, at MICs of ≤4 µg/ml. Against Enterobacteriaceae and Pseudomonas aeruginosa isolates, the potency of ceftobiprole was similar to that of cefepime.

* Corresponding author. Mailing address: Johnson & Johnson Pharmaceutical Research & Development LLC, 1000 Route 202 South, OMP B225, Raritan, NJ 08869. Phone: (908) 704-5425. Fax: (908) 707-3501. E-mail: kamsler{at}prdus.jnj.com

{triangledown} Published ahead of print on 30 June 2008.

Antimicrobial Agents and Chemotherapy, September 2008, p. 3418-3423, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.00336-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lemaire, S., Glupczynski, Y., Duval, V., Joris, B., Tulkens, P. M., Van Bambeke, F. (2009). Activities of Ceftobiprole and Other Cephalosporins against Extracellular and Intracellular (THP-1 Macrophages and Keratinocytes) Forms of Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 2289-2297 [Abstract] [Full Text]  
  • Kimko, H., Murthy, B., Xu, X., Nandy, P., Strauss, R., Noel, G. J. (2009). Population Pharmacokinetic Analysis of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 53: 1228-1230 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»